INCREASED CREATINE PHOSPHOKINASE AS A DIAGNOSTIC PROBLEM IN A MULTIMORBID PATIENT WITH COVID-19 (CLINICAL OBSERVATION)

Relevance. Creatine phosphokinase is an enzyme that is often associated with muscle and myocardial damage. However, there may be other causes of elevated levels of this enzyme, such as stroke, hypothyroidism, paraneoplastic syndrome, as well as various pharmacological effects, including taking statins and the development of statin-associated muscle symptoms, the consequences of a previous coronavirus infection - COVID-19.

The aim of the work is to determine the cause of an increase in creatine phosphokinase in a patient who has suffered a coronavirus infection against the background of concomitant diseases, and to conduct a differential diagnosis of an increase in this enzyme.

Results. An analysis of the patient's medical history with a significant increase in the level of creatine phosphokinase was performed and a subsequent differential diagnosis was carried out to identify the main causes of this change. The study was carried out based on the general condition of the patient, as well as the results of general and biochemical blood tests (including the level of creatine phosphokinase and lactate dehydrogenase), and instrumental studies were also carried out, such as electroneuromyography, electrocardiography, echocardiography and ultrasound.

Ischemic cardiovascular disease and hypothyroidism were identified. However, the increase in creatine phosphokinase levels was not associated with statin use, since they were discontinued during observation, and the enzyme level increased over time. Other causes of increased creatine phosphokinase were also excluded, and the results indicate that the increase in the level of this enzyme is likely caused by a previous coronavirus infection with concomitant diseases.

Conclusion. The present study highlights the importance of a comprehensive approach to the differential diagnosis and treatment of elevated creatine phosphokinase levels in patients with comorbid pathology, as this can be a consequence of various factors, including infections, concomitant diseases and pharmacological influences.

1. Руженцова Т.А., Милейкова Е.И., Моженкова А.В. и др. Значение повышения MB-креатинкиназы при различной экстракардиальной патологии. Лечащий врач. 2018;10:80–83 [Ruzhentsova T.A., Mileykova E.I., Mozhenkova A.V. et al. Role of increase of MB-creatine kinase in different extracardiac pathologies. Lechashchiy vrach. 2018;10:80–83 (In Russian)]. https://www.lvrach.ru/2018/10/15437115 [дата доступа: 28.05.2024].

2. Евдокимова Н.Е., Цыганкова О.В., Латынцева Л.Д. Синдром повышенной креатинфосфокиназы плазмы как диагностическая дилемма. РМЖ. 2021;2:18–25 [Evdokimova N.E., Tsygankova O.V., Latyntseva L.D. Evaluation of plasma creatine phosphokinase as a diagnostic dilemma. RMJ. 2021;2:18–25 (In Russian)]. https://www.elibrary.ru/download/elibrary_45816214_51212136.pdf [дата доступа: 28.05.2024].

3. Moghadam-Kia S., Oddis C.V., Aggarwal R. Approach to asymptomatic creatine kinase elevation. Cleve Clin J Med. 2016;83(1):37–42. DOI: 10.3949/ccjm.83a.14120.

4. Симптомы поражения мышц, обусловленные приемом статинов — влияние на тактику применения статинов: основные положения согласованного мнения экспертов Европейского общества по изучению атеросклероза о подходах к оценке, об этиологии и тактике ведения. Доказательная кардиология (электронная версия). 2015;(1):36‑46 [Symptoms of muscle damage caused by taking statins - impact on the tactics of using statins: the main provisions of the consensus opinion of experts from the European Society for the Study of Atherosclerosis on approaches to assessment, etiology and management tactics. Evidence-based Cardiology. 2015;(1):36‑46 (In Russian)]. DOI:10.17116/dokkardio2015136-46

5. Thygesen K., Alpert J.S., Jaffe A.S. et al. Executive Group on behalf of the Joint European Society of Cardiology (ESC) / American College of Cardiology (ACC) / American Heart Association (AHA) / World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). Glob Heart. 2018;13(4):305–338. DOI: 10.1016/j.gheart.2018.08.004

6. Rubegni A., Malandrini A., Dosi C. et al. Next-generation sequencing approach to hyperCKemia: A 2-year cohort study. Neurol Genet. 2019;5(5):e352. DOI:10.1212/NXG.0000000000000352

7. Invernizzi F., Izzo R., Colangelo I. et al. NGS-Based Genetic Analysis in a Cohort of Italian Patients with Suspected Inherited Myopathies and/or HyperCKemia. Genes (Basel). 2023;14(7):1393. DOI:10.3390/genes14071393

8. Руденская Г.Е., Миронович О.Л., Муртазина А.Ф., Щагина О.А. Разнообразие фенотипов, связанных с геном VCP: клиническое наблюдение и обзор литературы. Нервно-мышечные болезни. 2021;11(1):25-38 [Rudenskaya G.E., Mironovich O.L., Murtazina A.F., Shchagina O.A. Diversity of VCP-related phenotypes: case report and literature review. Neuromuscular Diseases. 2021;11(1):25-38 (In Russian)]. DOI:10.17650/2222-8721-2021-11-1-25-38

9. Mao L., Jin H., Wang M. et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77(6):683-690. DOI:10.1001/jamaneurol.2020.1127

10. Танашян М.М., Кузнецова П.И., Раскуражев А.А. Неврологические аспекты COVID-19. Анналы клинической и экспериментальной неврологии. 2020;14(2):62-69 [Tanashyan M.M., Kuznetsova P.I., Raskurazhev A.A. Neurological aspects of COVID-19. Annals of Clinical and Experimental Neurology. 2020;14(2):62-69 (In Russian)]. DOI:10.25692/ACEN.2020.2.8.

11. Гусев Е.И., Мартынов М.Ю., Бойко А.Н. и др. Новая коронавирусная инфекция (COVID-19) и поражение нервной системы: механизмы неврологических расстройств, клинические проявления, организация неврологической помощи. Журнал неврологии и психиатрии им. С.С. Корсакова. 2020;120(6):7 16 [Gusev E.I., Martynov M.U., Boyko A.N. et al. Novel coronavirus infection (COVID-19) and nervous system involvement: pathogenesis, clinical manifestations, organization of neurological care. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(6):7 16 (In Russian)]. DOI:10.17116/jnevro20201200617

12. Mach F., Baigent C., Catapano A.L. et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–188. DOI: 10.1093/eurheartj/ehz455.

13. Луговая Л.А., Стронгин Л.Г., Некрасова Т.А. Клинико-патогенетические особенности мышечных симптомов у больных компенсированным гипотиреозом, получающих терапию статинами. Фарматека. 2017;20:43–48 [Lugovaya L.A., Strongin L.G., Nekrasova T.A. Clinical and pathogenetic features of muscle symptoms in patients with compensated hypothyroidism receiving statin therapy. Pharmateca. 2017; 20:43–48 (In Russian)]. https://pharmateca.ru/ru/archive/article/35726 [дата доступа: 28.05.2024].

14. Петров А.В., Луговая Л.А., Стронгин Л.Г., Некрасова Т.А. Недиагностированный гипотиреоз — фактор риска возникновения рабдомиолиза при терапии статинами. Клиническая и экспериментальная тиреоидология. 2014;10(4):26–33. [Petrov A.V., Lugovaya L.A., Strongin L.G., Nekrasova T.A. Undiagosed hypothyroidism as risk factor of statin-induced rhabdomyolysis. Klinicheskaia I eksperimentalnaia tiroidologia. 2014;10(4):26–33 (In Russian)]. DOI: 10.14341/ket2014426_33.

15. Архипов В.В., Городецкая Г.И., Демидова О.А. и др. Анализ проблем безопасности применения статинов у пациентов с сахарным диабетом и гипотиреозом. Безопасность и риск фармакотерапии. 2019;7(4):163–175 [Arkhipov V.V., Gorodetskaya G.I., Demidova O.A. et al. Analysis of safety issues of using statins in patients with diabetes and hypothyroidism. Bezopasnost’ i risk farmakoterapii. 2019;7(4):163–175 (In Russian)]. DOI: 10.30895/2312-7821-2019-7-4-163-175

16. Демьяновская Е.Г., Крыжановский С.М., Васильев А.С., Шмырев В.И. Неврологические аспекты COVID-19. Тактика ведения пациентов неврологом с учетом эпидемиологической ситуации. Лечащий Врач. 2021;2(24):54-60 [Demianovskaia E.G., Kryzhanovskiy S.M., Vasiliev A.S., Shmirev V.I. Neurological aspects of COVID-19. Management of patients with neurological diseases considering epidemiological situation. Lechaschy Vrach. 2021;2(24):54-60 (In Russian)]. DOI: 10.26295/OS.2021.63.96.011

17. Ruan Q., Yang K., Wang W. et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846-848. DOI:10.1007/s00134-020-05991-x

18. Шостак Н.А., Клименко А.А., Демидова Н.А. и др. Скелетно-мышечные проявления новой коронавирусной инфекции: фокус на артралгии и миалгии. Клиницист. 2021;15(1-4):31-41 [Shostak N.A., Klimenko A.A., Demidova N.A. et al. Musculoskeletal manifectations of the new coronavirus infection: focus on arthralgia and myalgia. The Clinician. 2021;15(1-4):31-4 (In Russian)]. DOI: 10.17650/1818-8338-2021-15-1-4-K650